Latest Breaking News On - Hunter gillies - Page 4 : comparemela.com

Aerovate Therapeutics, Inc (NASDAQ:AVTE) Insider Sells $41,008 50 in Stock

Aerovate Therapeutics, Inc (NASDAQ:AVTE) Insider Sells $41,008 50 in Stock
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesHunter gilliesCrossover managementWells fargo companyAerovate therapeutics incDriehaus capital managementAerovate therapeutics company profileGreat point partnersSecurities exchange commissionCitadel advisorsAerovate therapeuticsGet free reportExchange commissionTherapeutics trading downCapital managementPoint partners

Aerovate Therapeutics (NASDAQ:AVTE) Shares Up 10 8%

Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Rating)’s stock price rose 10.8% on Thursday . The stock traded as high as $21.03 and last traded at $20.91. Approximately 27,694 shares traded hands during mid-day trading, a decline of 70% from the average daily volume of 92,888 shares. The stock had previously closed at $18.88. Wall Street […]

United statesTimothyp noyesHunter gilliesAerovate therapeutics company profileAerovate therapeutics incVr adviserGhost tree capitalAerovate therapeuticsGet ratingAsset managementAerovate therapeutics dailyNasdaq avte

Insider Selling: Aerovate Therapeutics, Inc (NASDAQ:AVTE) Insider Sells 4,000 Shares of Stock

Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Rating) insider Hunter Gillies sold 4,000 shares of the firm’s stock in a transaction on Friday, April 21st. The shares were sold at an average price of $19.50, for a total transaction of $78,000.00. Following the sale, the insider now owns 1,960 shares in the company, valued at $38,220. […]

United statesHunter gilliesTower research capitalBarclays plcGroup plcAerovate therapeutics company profileAerovate therapeutics incAerovate therapeuticsGet ratingTherapeutics trading downResearch capitalGeneral group plcAerovate therapeutics dailyNasdaq avteInsider tradingNsider trades

Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research

Phase 1 results showed that AV-101 was generally well tolerated with significantly reduced systemic exposure compared to oral imatinib in healthy adult participantsWALTHAM, Mass., Nov. 17, 2022 . | November 17, 2022

United statesHunter gilliesAerovate therapeutics incCompany twitterExchange commissionInternational conferenceAmerican thoracic societyChief medical officerThoracic societyAerovate therapeuticsPrivate securities litigation reform actAnnual reportNc stock exchangePress release022 avte us0080641071

Aerovate Therapeutics (AVTE) Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research

Aerovate Therapeutics (AVTE) Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesHunter gilliesAerovate therapeutics incInternational conferenceAmerican thoracic societyChief medical officer